EU Gives Hemophilia Sub-Q Injection Orphan Drug Designations

Alnylam Pharmaceuticals, Inc. (ALNY), a leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted Orphan Drug Designations for ALN-AT3 as an orphan medicinal product for the treatment of hemophilia A and hemophilia B. Alnylam is developing ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin […]

Living With a Bleeding Disorder Across the Decades

Blood Brotherhood is a national program for adult men with a bleeding disorder and provides a sense of community through education and support. The below articles are written by Blood Brothers enrolled in the program and features their stories of what growing up was like during different decades._____________________________________________ Carl | Severe Hemophilia  B | 1960s – 1970s […]

Octapharma’s Hemophilia A Product Approved in Europe

The European Commission has published approval of Octapharma’s Nuwiq ® (simoctocog alfa) for the treatment and prophylaxis of bleeding in all age groups with hemophilia A (congenital factor VIII [FVIII] deficiency). Nuwiq ® is the newest generation of FVIII replacement, produced in a human cell line cultured without additives of human or animal origin. Nuwiq […]